Article

In-Silico Analysis of Phytocompounds of *Olea europaea* as Potential Anti-Cancer Agents to Target PKM2 Protein

Faizan Abul Qais 1,*, Suliman Yousef Alomar 2,*, Mohammad Azhar Imran 3 and Md Amiruddin Hashmi 4

1 Department of Agricultural Microbiology, Faculty of Agricultural Sciences, Aligarh Muslim University, Aligarh UP-202002, India
2 Department of Zoology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
3 Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Korea
4 Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh UP-202002, India
* Correspondence: faqais@myamu.ac.in; Tel.: +91-571-2703516

Abstract: Globally, cancer is the second leading cause of mortality and morbidity. The growth and development of cancer are extremely complex. It is caused by a variety of pathways and involves various types of enzymes. Pyruvate kinase M2 (PKM2) is an isofrom of pyruvate kinase, that catalyses the last steps of glycolysis to produce energy. PKM2 is relatively more expressed in tumour cells where it tends to exist in a dimer form. Various medicinal plants are available that contain a variety of micronutrients to combat against different cancers. The phytocompounds of the olive tree (*Olea europaea*) leaves play an important role in inhibiting the proliferation of several cancers. In this study, the phytocompounds of olive leaf extract (OLE) were studied using various in silico tools, such as pkCSM software to predict ADMET properties and PASS Online software to predict anticancer activity. However, the molecular docking study provided the binding energies and inhibition constant and confirmed the interaction between PKM2 and the ligands. The dynamic behaviour, conformational changes, and stability between PKM2 and the top three hit compounds (Verbascoside (Ver), Rutin (Rut), and Luteolin_7_O_glucoside (Lut)) are studied by MD simulations.

Keywords: pyruvate kinase M2 (PKM2); virtual screening; ADMET analysis; molecular docking; molecular dynamic simulations

1. Introduction

Cancer is initiated by alterations in the human genome that enhance cellular proliferation through variation in normal pathways and mechanisms. However, cancer is the second prominent cause of death worldwide [1]. The development of cancer is an extremely complex process, therefore, it is recognized as a multifactorial disease [2]. The main difference between cancer and normal cells is that, even when there is adequate oxygen available in the surroundings, cancer cells are completely dependent on aerobic glycolysis to generate energy. During glucose metabolism, pyruvate kinase catalyses the last step of the conversion of phosphate unit from phosphoenolpyruvate to ADP to form the end-products as pyruvate and ATP. Under aerobic conditions, tumour cells continue to convert glucose to lactate, and this phenomenon is termed the Warburg effect [3]. In mammals, there are four main types of pyruvate kinase (PK) isomers, which include PKL, PKR, PKM1, and PKM2. PKL is mainly expressed in the liver, intestine, and kidney, whereas PKR is primarily up-regulated in RBC [4]. PKM1 is expressed in the muscles, heart, and brain. However, PKM2 is up-regulated in tumours and embryonic tissues of proliferating cells [5]. In healthy tissues, PKM2 proteins transit between the tetrameric form to dimeric form. Moreover, in tumour cells, PKM2 exist in the dimeric form. The low catalytic activity of dimeric PKM2 increases the anabolic synthesis of protein through the pentose phosphate pathway and thus, stimulates the growth and development of cancer cells [6].
Olive tree (*Olea europaea*) leaves have been widely used in folk medicine in the European Mediterranean area, India, Arabian peninsula, and other tropical and subtropical regions for the treatment of inflammation, allergies, diarrhea, and diseases such as Alzheimer’s, chronic fatigue syndrome, and osteoarthritis [7]. The bioactive composites of olive leaf extract (OLE) contain a higher quantity and variety of microconstituents than extra virgin olive oil (Table 1). There is also a structural difference between the phyto-compounds of OLE that shows a great enhancement to health outcomes compared with olive fruit [8]. It has been proposed that the OLE plays an important protective role in inhibiting the proliferation of several cancer cell lines including pancreatic, leukaemia, breast, prostate, and colorectal [9]. There are numerous bioactive compounds of OLE that are studied for the inhibition of progression and development of different types of cancers. A study conducted on flavonoids of OLE against HeLa cervical cancer cells reported that its increasing concentrations resulted in decreased cancer cell viability. The major compounds detected in the extract were luteolin-4′-O-glucoside, apigenin-7-O-glucoside, and rutin [10]. Similarly, another study found a cytotoxic effect of OLE extract on MCF-7 breast and HepG2 hepatocellular carcinoma cells [11]. Some of the compounds of OLE have been reported to induce apoptosis and inhibit proliferation in the cancer cells due to its potential anticancer activity [12]. In this study, we utilized in-silico approaches such as (i) pharmacoinformatics to predict the toxicity, anticancer, and pharmacokinetics properties of the selected phyto-compounds against PKM2, (ii) molecular docking, and (iii) molecular dynamic simulations for evaluation of the conformational changes, stability, and intermolecular interactions between PKM2 and the phytocompounds. This study aims to identify the potential lead phytocompounds from OLE to combat PKM2-related cancer in the coming future.

Table 1. List of bioactive compounds, their micro constituents and molecular formula present in olive leaf extract (OLE).

| Compound Names                  | Micro Constituent             | Formula         | Reference |
|--------------------------------|-------------------------------|-----------------|-----------|
| Rutin                          | Flavonoid                      | C27H30O16       | [13]      |
| Luteolin_7_O_glucoside         | Flavonoid                      | C21H20O11       | [14]      |
| Verbascoside                   | Phenolic compound              | C29H36O15       | [13]      |
| Maslinic acid                  | Triterpenoid                   | C30H48O4        | [15]      |
| Oleuropein                     | Secoiridoid                    | C25H32O13       | [1]       |
| Lucidumoside C                 | Secoiridoid                    | C27H36O14       | [14]      |
| Ursolic acid                   | Triterpenoid                   | C30H48O3        | [13]      |
| Oleancolic acid                | Triterpenoid                   | C30H48O3        | [13]      |
| Uvaol                          | Phenolic compound              | C30H50O2        | [15]      |
| Betulinic acid                 | Triterpenoid                   | C30H48O3        | [16]      |
| Oleoside                       | Secoiridoid                    | C16H22O11       | [13]      |
| Elenolic acid glucoside        | Secoiridoid                    | C17H25O11       | [13]      |
| Loganic acid                   | Phenolic compound              | C16H24O10       | [17]      |
| Diosmetin                      | Flavone glycoside              | C21H13O11       | [18]      |
| Apigenin                       | Flavonoid                      | C15H10O5        | [13,14]   |
| Secologanin                    | Phenolic compound              | C17H24O10       | [17]      |
| Ferulic acid                   | Phenolic compound              | C10H10O4        | [19]      |
| Hydroxytyrosol                 | Phenolic compound              | C8H10O3         | [13]      |
| Gallic acid                    | Phenolic compound              | C7H6O5          | [20]      |
| Coumaric acid                  | Phenolic compound              | C9H8O3          | [21]      |
| Homovanillic Alcohol           | Phenolic compound              | C9H12O3         | [13]      |
| Cinnamic acid                  | Phenolic compound              | C9H8O2          | [13]      |
| Tyrosol                        | Phenolic compound              | C8H10O2         | [22]      |
2. Materials and Methods

2.1. Preparation of the Phytocompounds Database

The three-dimensional structure of the phytocompounds of OLE was retrieved from PubChem (www.pubchem.ncbi.nlm.nih.gov) in the format of SDF. The molecules were then converted to PDB format using Chimera 1.14 software (California, SF, USA) [23]. The PDB file was further used for molecular docking.

2.2. Prediction of ADMET Properties

Computational pharmacokinetics in an in-silico approach was used to determine the time course of drug absorption, distribution, metabolism, excretion, and toxicity (ADMET). In the early stages of the selection of phytocompounds, ADMET properties support and define the efficiency and integrity of the active compounds. To estimate the ADMET properties of phytocompounds, pkCSM server was used [24]. Toxicity can be evaluated by measuring the degree of the quality of a chemical substance being poisonous to humans or animals and that can damage an organ. It is very important to evaluate the harmful effect of chemical compounds before undergoing a drug trial. Toxicity evaluation is one of the main and vital steps in the drug design process [25].

2.3. Prediction of Anticancer Activity

The in-silico prediction of anticancer properties of the selected phytocompounds were further studied by using a web server named PASS-Way2Drug server. The PASS (Prediction of Activity Spectra for Substances) gives p values for the similarity measures based on which anticancer activity is predicted as highly possible or less possible [26]. It can hit 65% positive results at a rate of 0.05 false-positive outcomes. Since it requires the canonical Simplified Molecular Input Line Entry String (SMILES) of compounds to be investigated, we used the PubChem server as sources of required entries.

2.4. Retrieval and Preparation of Protein

In this study, the 3D structure of the PKM2 (PDB ID: 3BJF) obtained by X-ray diffraction with a resolution of 2.03 Å was retrieved from RCBS, Protein Data Dank (https://www.rcsb.org/, accessed on 8 June 2022). The human PKM2 protein is a homo-tetramer with a molecular weight of 228.50 kDa. Each chain contains 518 residues. The ions, water molecules, and other ligands were removed to make a clean PDB structure. The only monomeric structure of PKM2 was taken for molecular docking and simulation studies. A detailed procedure is given in the molecular docking section.

2.5. Screening of Potential Lead Compounds

The active site of enzymatic proteins contains a catalytic site, where the substrate binds, and the reaction is catalysed forming the product. Mammalian PKM2 is a tetrameric protein with identical subunits. Each monomer contains one active site and is composed of three main domains—designated A, B, and C—plus a small N-terminal domain. Molecular docking is a well-known screening tool that can analyse the best binding mode of a ligand to a targeted macromolecule. The molecular docking was performed using AutoDock-Vina software (La Jolla, CA, USA) [27]. The receptor molecule (PKM2) was cleaned before preparation. The non-polar hydrogen was added and then Kollman charges were added. The spacing of the grid was set to 1 Å. The size of the grid was 60 × 72 × 92 with centre as x = 3.580, y = −18.461, and z = 27.361. The receptor was finally saved into PDBQT format using MGLTools 1.5.6. The ligand molecules were made flexible by detecting the roots to obtain the best possible conformation. The ligands were saved in PDBQT format. The analysis of molecular docking was performed using LigPlot+ (Cambridge, UK), Discovery Studio 2021, AutoDock Tools (La Jolla, CA, USA), and PyMOL [28–30].
2.6. Molecular Dynamics Simulations

The top three compounds, Rut, Lut, and Ver, exhibiting the highest binding affinity towards PKM2 were used for further studies using molecular dynamics (MD) simulations. For these selected compounds, the docked conformations with the lowest binding energy were taken as the initial structure of MD simulation. The MD simulations were performed on Gromacs 2018.1 package using amber99sb-ILDN force field [31,32]. The topology of the ligands was generated with Antechamber packages in AmberTools21 [33]. PKM2 alone was also simulated as a control. All systems were solvated in a triclinic box using the TIP3P water model followed by their neutralization by adding 3 chlorine ions. The energy of the system was minimized using a maximum of 50,000 steps to remove the weak van der Waals contacts. The systems were equilibrated for NVT and NPT for 1 ns, each using a V-rescale thermostat at 310 K and using Parrinello-Rahman barostat at 1.0 bar, respectively. The equilibrated structure was finally used to perform 100 ns MD simulations. Three replicates of each system were simulated, and the data are presented as averages. Each trajectory and all trajectories were subjected to periodic boundary conditions (PBC) corrections before analysis. Using Gromacs utilities, root mean square deviation (RMSD) of the backbone was calculated for initial conformation. Furthermore, root mean square fluctuations (RMSF), hydrogen bond analysis, solvent accessible surface area analysis (SASA), radius of gyration (Rg), secondary structure of protein, etc., were calculated. The principal complement analysis (PCA) was calculated using gmx covar utility of gromacs that calculates and diagonalizes the covariance matrix and a new trajectory file. The new trajectory written was then analysed by gmx anaeig in which all structures are fitted to the structure in the eigenvector file. The free energy landscape was made using gmx sham utility. The quantitative evaluation of the interaction of ligands with PKM2 was done using MM-PBSA calculation [34].

3. Results and Discussion

3.1. Prediction of ADMET Properties

The preliminary analysis of the phytocompounds of OLE was performed for its ability to cause toxicity in different models using in-silico tools. Compared with the conventional methods, computer-aided toxicity tests are fast and inexpensive methods that eliminate potentially toxic chemical compounds at an initial stage and reduce many biological experimental tests. Using the pkCSM web server, the toxicity of all compounds was predicted. The drug-induced AMES toxicity, hepatotoxicity, skin sensitization, and Tetrahymena pyriformis toxicity, and oral rat acute toxicity of selected compounds are listed in Table 2. AMES toxicity measures the mutagenic potential of compounds [35]. Out of all tested compounds, only the hydroxytyrosol showed AMES toxicity. In hepatotoxicological assessment, five compounds namely ursolic acid, oleaolic acid, uvaol, betulinic acid, and maslinic acid, were predicted positive. Similarly, only tyrosol was found to exhibit skin sensitization properties. T. pyriformis is one of the most routinely used model organisms to test the toxicity of compounds [36]. All compounds showed very low or negligible toxicity in the T. pyriformis model of toxicity. This indicates that most of the tested compounds were not toxic to T. pyriformis-based toxicity. For instance, there is no inhibition of human ether-a-go-go-related gene 1 (hERG-1) K⁺ channels in this study. The hERG-1 is toxic for the heart and may produce lethal cardiac arrhythmia. Therefore, early-stage identification of putative hERG inhibitors or non-inhibitors may play an important role in reducing cardiotoxicity. Moreover, the oral rat acute toxicity of all compounds was also evaluated. In all compounds, except lucidumoside C, the oral rat acute toxicity was found to be below 3 log µg/l. Based on the toxicological assessment of selected compounds, it may be inferred that most of the phytocompounds of OLE were not found to exhibit toxicity. The ADME properties of the phytocompounds predicted by the pkCSM web server indicate relevant pharmaceutical properties for most of the compounds as shown in Table 3.
Table 2. Assessment of the toxicity of different bioactive compounds of olive leaf extract (OLE) using pkCSM webserver.

| Compound Names | AMES Toxicity | hERG-I Inhibitor | Hepato-Toxicity | Skin Sensitisation | T. pyriformis Toxicity (log µg/L) | Oral Rat Acute Toxicity (mol/kg) |
|----------------|---------------|------------------|-----------------|--------------------|----------------------------------|----------------------------------|
| Rutin          | No            | No               | No              | No                 | 0.285                            | 2.491                            |
| Verbascoside   | No            | No               | No              | No                 | 0.285                            | 2.527                            |
| Luteolin_7_O_glucoside | No   | No               | No              | No                 | 0.285                            | 2.547                            |
| Ursolic acid   | No            | No               | Yes             | No                 | 0.285                            | 2.346                            |
| Oleanolic Acid | No            | No               | Yes             | No                 | 0.285                            | 2.349                            |
| Oleuropein     | No            | No               | No              | No                 | 0.285                            | 2.862                            |
| Maslinic acid  | No            | No               | Yes             | No                 | 0.285                            | 2.516                            |
| Uvaol          | No            | No               | Yes             | No                 | 0.376                            | 2.646                            |
| Betulinc acid  | No            | No               | Yes             | No                 | 0.285                            | 2.256                            |
| Apigenin       | No            | No               | No              | No                 | 0.38                             | 2.45                             |
| Loganic acid   | No            | No               | No              | No                 | 0.285                            | 1.995                            |
| Oleoside       | No            | No               | No              | No                 | 0.285                            | 2.389                            |
| Diosmetin      | No            | No               | No              | No                 | 0.336                            | 2.338                            |
| Elenolic acid glucoside | No | No | No | No | 0.285 | 2.35 |
| Lucidumoside C | No            | No               | No              | No                 | 0.285                            | 3.068                            |
| Secologanin    | No            | No               | No              | No                 | 0.285                            | 2.031                            |
| Coumaric acid  | No            | No               | No              | No                 | 0.319                            | 2.155                            |
| Cinnamic acid  | No            | No               | No              | No                 | 0.247                            | 2.094                            |
| Ferulic acid   | No            | No               | No              | No                 | 0.271                            | 2.282                            |
| Hydroxytyrosol | Yes           | No               | No              | No                 | −0.128                           | 1.858                            |
| Gallic acid    | No            | No               | No              | No                 | 0.285                            | 2.218                            |
| Tyrosol        | No            | No               | No              | Yes                | −0.244                           | 1.861                            |
| Homovanillyl alcohol | No | No | No | No | −0.059 | 1.891 |

1/total 0/total 5/total 1/total

T. pyriformis toxicity- Aquatic toxicity model. Oral Rat Acute Toxicity is presented as LD50.

Table 3. Evaluation of the ADME properties of the phytocompounds present in the olive leaf extract (OLE) using pkCSM web server for human model.

| Compound Names | Water Solubility (log mol/L) | Intestinal Absorption (%) | Fraction Unbound (Fu) | CYP3A4 Inhibitor | Total Clearance (log mL/min/kg) |
|----------------|------------------------------|----------------------------|-----------------------|------------------|-------------------------------|
| Rutin          | −2.892                       | 3.446                      | 0.187                 | No               | −0.369                        |
| Verbascoside   | −2.906                       | 32.119                     | 0.269                 | No               | 0.479                         |
| Luteolin_7_O_glucoside | −2.716 | 37.556                      | 0.224                 | No               | 0.478                         |
| Ursolic acid   | −3.072                       | 100                        | 0                     | No               | 0.083                         |
| Oleanolic Acid | −3.074                       | 99.931                     | 0                     | No               | 0.285                         |
| Oleuropein     | −2.722                       | 44.206                     | 0.485                 | No               | 1.176                         |
| Maslinic acid  | −3.042                       | 100                        | 0.033                 | No               | −0.071                        |
| Uvaol          | −5.947                       | 92.819                     | 0                     | No               | 0.206                         |
| Betulinc acid  | −3.122                       | 99.763                     | 0.018                 | No               | 0.116                         |
| Apigenin       | −3.329                       | 93.25                      | 0.147                 | No               | 0.566                         |
| Loganic acid   | −2.365                       | 16.515                     | 0.641                 | No               | 1.225                         |
| Oleoside       | −2.604                       | 0                          | 0.567                 | No               | 1.395                         |
| Diosmetin      | −3.238                       | 79.898                     | 0.068                 | No               | 0.598                         |
| Elenolic acid glucoside | −2.517 | 20.4                       | 0.606                 | No               | 1.482                         |
| Lucidumoside C | −2.833                       | 41.241                     | 0.418                 | No               | 1.146                         |
| Secologanin    | −2.676                       | 40.54                      | 0.611                 | No               | 1.585                         |
| Coumaric acid  | −2.378                       | 93.494                     | 0.428                 | No               | 0.662                         |
| Cinnamic acid  | −2.608                       | 94.833                     | 0.38                  | No               | 0.781                         |
| Ferulic acid   | −2.817                       | 93.685                     | 0.343                 | No               | 0.623                         |
| Hydroxytyrosol | −1.139                       | 72.809                     | 0.593                 | No               | 0.23                          |
| Gallic acid    | −2.56                        | 43.374                     | 0.617                 | No               | 0.518                         |
| Tyrosol        | −1.146                       | 85.255                     | 0.485                 | No               | 0.283                         |
| Homovanillyl alcohol | −1.433 | 84.608                      | 0.395                 | No               | 0.305                         |
3.2. Prediction of Anticancer Activity

Prior to docking, the potential cellular targets of phytocompounds of OLE were also identified through the PASS Online software (http://www.way2drug.com/passonline). Using PASS Online, we only predicted the anticancer activity in which two main parameters, pyruvate kinase inhibition and antineoplastic properties, were considered. The reason for selection of these two parameters is that this study focuses on the screening of compounds against pyruvate kinase. The PASS Online server predicts the biological activities of compounds and presents the results in the form of indices of the biological activity or inactivity [26]. There are probabilities of either presence of biological activity (Pa) or absence of biological inactivity (Pi). The predicted pyruvate kinase inhibition and antineoplastic properties of compounds of OLE are listed in Table 4. For pyruvate kinase inhibition, the Pa values of all compounds were more than Pi, showing the probability of biological activity compared with inactivity. It is interesting to note that Pa values of the top three compounds were far more than the Pi values. This shows the greater probability of these hit compounds to inhibit the pyruvate kinase. Similarly, Pa values for antineoplastic properties of selected compounds were also far more than Pi values. These two parameters indicate higher chances of anticancer activity of these compounds.

Table 4. Anti-cancer predictions of the phytocompounds present in the olive leaf extract (OLE) using Way2Drug (pass) server.

| Compound Name         | Pyruvate Kinase Inhibition | Antineoplastic |
|-----------------------|----------------------------|----------------|
|                       | Pa            | Pi            | Pa            | Pi            |
| Rutin                 | 0.229         | 0.009         | 0.849         | 0.007         |
| Luteolin_7-O-glucoside| 0.680         | 0.002         | 0.830         | 0.009         |
| Verbascoside          | 0.115         | 0.017         | 0.814         | 0.010         |
| Maslinic              | --            | --            | 0.867         | 0.005         |
| Oleuropein            | --            | --            | 0.387         | 0.109         |
| Lucidumoside C        | --            | --            | 0.674         | 0.030         |
| Ursolic acid          | --            | --            | 0.857         | 0.006         |
| Oleanolic acid        | --            | --            | 0.876         | 0.005         |
| Uvaol                 | --            | --            | 0.907         | 0.005         |
| Betulinic acid        | --            | --            | 0.925         | 0.005         |
| Oleoside              | 0.091         | 0.025         | 0.796         | 0.012         |
| Elenolic acid glucoside| 0.063       | 0.050         | 0.795         | 0.012         |
| Loganic acid          | 0.071         | 0.040         | 0.817         | 0.010         |
| Diosmetin             | 0.135         | 0.014         | 0.791         | 0.013         |
| Apigenin              | 0.280         | 0.007         | 0.774         | 0.015         |
| Secologanin           | --            | --            | 0.500         | 0.071         |
| Ferulic acid          | 0.080         | 0.031         | 0.601         | 0.045         |
| Hydroxytyrosol        | 0.119         | 0.016         | --            | --            |
| Gallic acid           | 0.124         | 0.016         | 0.313         | 0.145         |
| Coumaric acid         | 0.163         | 0.011         | 0.520         | 0.065         |
| Homovanillyl alcohol  | 0.070         | 0.040         | 0.321         | 0.140         |
| Cinnamic acid         | 0.141         | 0.013         | 0.455         | 0.085         |
| Tyrosol               | 0.132         | 0.014         | --            | --            |

It is documented that both the extract and phytocompounds of OLE plays a protective role in the inhibition and proliferation of several cancer cell lines such as pancreatic cancer, leukaemia, breast, prostate, colorectal etc. [9]. Moreover, certain bioactive compounds of OLE have also been found to reduce the progression of some cancer types. For insurance, the flavonoids of OLE were found to be effective against HeLa cervical cancer cells and also decreased cancer cell viability. The major compounds detected in the extract were luteolin-4’-O-glucoside, apigenin-7-O-glucoside, and rutin [10]. Similarly, another study found the cytotoxic effect of OLE extract on the MCF-7 breast, HepG2 hepatocellular carcinoma cells [11].
3.3. Screening of Potential Phytocompounds

The molecular docking study was performed for virtual screening and to determine the best intermolecular interaction between the PKM2 protein and the phytocompounds. In this study, the selected phytocompounds of OLE were docked using Autodock-Vina software. The docking with Autodock-vina gave nine best conformations in which the conformation with lowest binding energy was considered. The binding energies and inhibition constant of compounds against PKM2 are listed in Table 5. Most of the compounds exhibited good binding affinity towards PKM2 and binding energies ranged from $-5.7$ to $-10.0$ kcal/mol. A total of 13 compounds were found to be docked at the catalytic site of PKM2. Only three compounds were found to bind at the allosteric site and the rest of the phytocompounds were found to interact at the other sites, i.e., sites other than catalytic and allosteric site. The top three compounds that were identified on the overall basis of binding energy, binding site, pharmacokinetics data, ADMET properties, predicted anticancer activities were Rut, Ver, and Lut. It is interesting to note that these three compounds were docked at the catalytic site of PKM2. The inhibition constant of Rut, Ver, and Lut were found to be 0.046, 0.064, and 0.296 µmol/l, respectively. The data clearly shows the potency of these compounds to inhibit PKM2 at very low concentrations. Rut interacted with Asp296, Glu332, His78, Arg120, and Arg73 of PKM2 via hydrogen bonds (Figure 1B). Asp178 formed hydrophobic interacts with Rut. Similarly, Asn210, Gly363, Asn75, Ile51, Arg73, Glu272, Lys270, Asp296, Thr328, and Ser362 formed hydrogen binds with Lut (Figure 1A). Other amino acids were involved in hydrophobic interactions. Ver was found to make hydrogen bonds with Glu118, Glu272, Thr328, Ser362, Asn75, Gly52, and Asp296 (Figure 1C). The 3D docked structure of the top three complexes are shown in Figure 1. The data clearly show the strong affinity of these compounds with PKM2 which paves the way for exploration of their therapeutic effects under in vitro and in vivo models.

Table 5. Screening of the phytocompounds to obtain potential lead molecules (bold) based on their respective binding energy profile upon docking with PKM2 using Autodock vina.

| Compound Names                      | PubChem CID | Binding Energy (kcal/mol) | Ki (µmol/L) | Binding Site |
|-------------------------------------|-------------|---------------------------|-------------|--------------|
| Rutin                               | 5280805     | $-10$                     | 0.046       | CS           |
| Verbascoside                        | 5281800     | $-9.8$                    | 0.064       | CS           |
| Luteolin_7_O_glucoside             | 5280637     | $-8.9$                    | 0.296       | CS           |
| Ursolic acid                        | 64945       | $-8.9$                    | 0.296       | CS           |
| Oleanolic Acid                      | 10494       | $-8.8$                    | 0.351       | CS           |
| Oleuropein                          | 5281544     | $-8.8$                    | 0.351       | CS           |
| Maslinic                            | 73659       | $-8.7$                    | 0.415       | OS           |
| Uvaol                               | 92802       | $-8.7$                    | 0.415       | OS           |
| Betulinic acid                      | 64971       | $-8.4$                    | 0.690       | OS           |
| Apigenin                            | 5280443     | $-8.1$                    | 1.145       | OS           |
| Loganic acid                        | 89640       | $-8$                      | 1.356       | CS           |
| Oleoside                            | 101042548   | $-8$                      | 1.356       | CS           |
| Diosmetin                           | 5281612     | $-9$                      | 0.250       | CS           |
| Elenolic acid glucoside             | 10692563    | $-7.6$                    | 2.665       | CS           |
| Lucidumoside C                      | 10793430    | $-7.5$                    | 3.155       | CS           |
| Secologanin                         | 161276      | $-7.1$                    | 6.201       | CS           |
| Coumaric acid                       | 637542      | $-6.9$                    | 8.693       | AS           |
| Cinnamic acid                       | 444539      | $-6.4$                    | 20.226      | CS           |
| Ferulic acid                        | 445858      | $-6.3$                    | 23.947      | OS           |
| Hydroxytyrosol                      | 82755       | $-6.3$                    | 23.947      | AS           |
| Gallic acid                         | 370         | $-6$                      | 39.746      | CS           |
| Tyrosol                             | 10393       | $-6$                      | 39.746      | AS           |
| Homovanillyl alcohol                | 16928       | $-5.7$                    | 65.968      | CS           |

Ki: Inhibition content; AS: allosteric site, CS: catalytic site; OS: other site (other than catalytic and allosteric site).
Ursolic acid 64945 −8.9 0.296 OS
Oleanolic Acid 10494 −8.8 0.351 CS
Oleuropein 5281544 −8.8 0.351 CS
Maslinic 73659 −8.7 0.415 OS
Uvaol 92802 −8.7 0.415 OS
Betulinic acid 64971 −8.4 0.690 OS
Apigenin 5280443 −8.1 1.145 OS
Loganic acid 89640 −8 1.356 CS
Oleoside 101042548 −8 1.356 CS
Diosmetin 5281612 −9 0.250 CS
Elenolic acid glucoside 10692563 −7.6 2.665 CS
Lucidumoside C 10793430 −7.5 3.155 CS
Secologanin 161276 −7.1 6.201 CS
Coumaric acid 637542 −6.9 8.693 AS
Cinnamic acid 444539 −6.4 20.226 CS
Ferulic acid 445858 −6.3 23.947 OS
Hydroxytyrosol 82755 −6.3 23.947 AS
Gallic acid 370 −6 39.746 CS
Tyrosol 10393 −6 39.746 AS
Homovanillyl alcohol 16928 −5.7 65.968 CS

Ki: Inhibition content; AS: allosteric site, CS: catalytic site; OS: other site (other than catalytic and allosteric site).

Figure 1. 2D and 3D representation of the docked structures of the top three lead molecules showing the residues involved in the interaction of the protein-ligand complexes. (A) PKM2-Lut complex; (B) PKM2-Rut complex; (C) PKM2-Ver complex.

3.4. Molecular Dynamics Simulation
3.4.1. Analysis of RMSD and RMSF

The preliminary analysis of the molecular dynamics simulation data was performed by calculating the RMSD of all systems with respect to their respective initial conformations. The RMSD values provide an idea regarding the stability of proteins/complexes during MD simulation studies. The RMSD of all systems are shown in Figure 2A. The RMSD of all systems exhibited some variations until 40 ns and then the systems became stable. This shows that all systems were well equilibrated after 40 ns. The average RMSD of PKM2 alone was found to be 0.311 nm. Similarly, the RMSD of the PKM2-Ver complex, PKM2-Rut complex, and PKM2-Lut complex was found to be 0.317, 0.313, and 0.305 nm, respectively. A slight increase in RMSD values compared with PKM2 alone is due to the dynamic behavior of ligands in the binding pocket. The RMSDs of binding pocket residues were also calculated as shown in Figure 2B. The average RMSD of the binding pocket of PKM2 alone was obtained as 0.336 nm, whereas the RMSD of the binding pocket of PKM2-Ver complex, PKM2-Rut complex, and PKM2-Lut complex were 0.279, 0.234, and 0.236 nm, respectively. It is interesting to note that the RMSD of binding pocket of all complexes decreased compared with that of PKM2 alone which is due the stabilization of the binding region after interaction of the ligands. The fluctuation in all amino acids of PKM2 alone and the complexes were studied by calculating the RMSF of Cα of the residues, as presented in Figure 3A. The RMSF of most of the amino acids of were found to be less than 0.25 nm, further indicating the stable nature of the systems. There were certain spikes in RMSF which are attributed to the loops and coils of PKM2 that tend to fluctuate in aqueous environments. The RMSF of each atom of all ligands were also calculated to obtain their dynamic behaviour (Figure 3B). Out of all ligands, Lut was found to exhibit the least dynamic behaviour. Other ligands, Rut and Ver, showed relatively more fluctuation indicating their dynamic behaviour in the binding pocket. This dynamic behaviour may be attributed to the rotatable bonds and the changes in interaction at binding site. As evident from the docking studies, the binding site of these three ligands were at the catalytic site.
of PKM2. This shows that ligands exhibited dynamical shift for their respective initial positions at the catalytic site of the protein.

![Figure 2](image-url) (A) Root mean square deviation (RMSD) of the backbone atoms of PKM2 and its complexes with Ver, Rut, and Lut over 100 ns of simulation. (B) RMSD of the binding pocket residues of PKM2 in the absence and presence of ligands (Ver, Rut, and Lut). The data presented are averages of three independent simulations.

![Figure 3](image-url) (A) Root mean square fluctuation (RMSF) of Cα of each residue of PKM2 and its complexes with the Ver, Rut, and Lut. (B) The average RMSF of each atom of ligands (Ver, Rut, and Lut). The data presented are averages of three independent simulations.

3.4.2. Analysis of Physicochemical Parameters, Structure Compactness and Secondary Structure

Further detailed analysis of PKM2 and its complexes in aqueous environment was performed in order to validate the stability of each system and their physicochemical parameters, such as total and potential energies (Figure 4A). The potential energy of all complexes remained constant and equal to the PKM2 alone. Similarly, the total energy of all systems was found to be uniform throughout the simulation. These parameters show the stability of systems in physiological conditions [37]. The mass-weighted RMS distance of the collection of atoms from their common centre of mass is termed as radius of gyration (Rg). Typically, compact proteins such as globular proteins have relatively lower radius variations in Rg compared with the expanded form of proteins [38]. The Rg values are taken as an important parameter to study the structural compactness and stability of proteins or complexes during MD simulation [39]. The Rg of PKM2 alone and its complexes are presented in Figure 4B. The average Rg of PKM2 alone was found to be 2.471 nm. Similarly, the Rg of PKM2-Ver, PKM2-Rut, and PKM2-Lut complexes were obtained as 2.458, 2.470, and 2.459 nm, respectively. The data shows the stable nature of complexes. Moreover,
solvent accessible surface area (SASA) of all systems were also calculated as shown in Figure 5A. The average SASA of PKM2 alone was recorded as 234.430 nm². The SASA of PKM2-Ver, PKM2-Rut, and PKM2-Lut complexes were found to be 232.062, 235.464, and 235.980 nm², respectively. As evident from the data there were negligible change in the SASA of all complexes compared with PKM2 alone and the uniformity in the results further validates the stability of systems in physiological conditions.

![Figure 4](image1.png)

**Figure 4.** (A) Potential and total energy of PKM2 and its complexes with Ver, Rut, and Lut. (B) Radius of gyration (Rg) of PKM2 in the absence and presence of Ver, Rut, and Lut as a function of simulation time. The data presented are averages of three independent simulations.

![Figure 5](image2.png)

**Figure 5.** Number of hydrogen bonds formed between PKM2-Ver, PKM2-Rut, and PKM2-Lut complexes over the entire course of simulation.

The effect of binding of ligands on the structural stability of PKM2 was investigated by calculating secondary structure of the protein in complexed and un-complexed form. Each of the secondary structural components in PKM2 alone and complexes are shown in Figure 5B. The percentage of coils, β-Sheet, β-Bridge, bends, turns, α-helix, and 3'-helix in PKM2 alone was found to be 18.02, 19.81, 1.13, 11.81, 12.86, 32.92, and 3.42, respectively. There was no significant change in any of these motifs of PKM2 in the presence of individual ligands (Ver, Rut, and Lut). This confirms and finally validates the structural stability of all simulated complexes.

### 3.4.3. Analysis of Hydrogen Bonds and Binding Energies

To study the interaction between the ligands and PKM2, hydrogen bond profiles of all systems were calculated. First, the number of hydrogen bonds of the entire trajectories was calculated (Figure 6A). The average number of hydrogen bonds in all frames for PKM2-Ver, PKM2-Rut, and PKM2-Lut complexes were found to be 4.840, 5.801, and 4.323, respectively.
This shows that Rut formed more hydrogen bonds with PKM2 than the other two ligands (Ver, Lut). The finding supports the docking studies where Rut showed the highest binding affinity towards the protein. The analysis of hydrogen bond profiles showed the existence of hydrogen bonds throughout the entire simulation period (Figure 6B–D). The shift in hydrogen bond profiles with time indicates that hydrogen bonds between the ligands and PMK2 were dynamic in nature [40]. Moreover, the fluctuation in hydrogen bonds may also be due to the interaction of water molecules at the binding site that may be resulting in fluctuation of the hydrogen bond profiles [41]. The occupancy of hydrogen bonds with more than 1.0% was also calculated. For the binding of PKM2-Ver and PKM2-Lut complexes, Asn75 showed the highest occupancy at 42.2% and 63.4%, respectively. Similarly, Glu364 of PKM2 was found to exhibit the highest hydrogen bond occupancy of 46.0% with Rut. Many other amino acids of PKM2 were also involved in the hydrogen bond formation with these ligands.

The interaction of the ligands with PKM2 was further studied using MM-PBSA calculations. A total of 100 frames from the entire trajectory of each complex at 1 ns interval was extracted for MM-PBSA analysis. In protein–ligand interactions, the non-covalent forces such as electrostatic, hydrophobic, van der Waals forces, and hydrogen bonds are predominant. These forces either contribute positively or negatively in the overall binding [42]. Various binding energies were calculated using MM-PBSA methods and the results are listed in Table 6. Electrostatic and van der Waals forces were predominant in the interaction of ligands with PKM2. There was also a small contribution of SASA energy in the total binding energy. However, polar solvation energy impaired the binding of ligands with PKM2 as evident from its positive values. The total binding energy for the interaction of Ver, Rut, and Lut with PKM2 was found to be −7.76, −3.22, and −15.00 kcal/mol, respectively.
Table 6. Binding free energy of ligands with PKM2 calculated by the MM-PBSA method for 100 snapshots of MD simulation.

| Ligands          | Verbascoside | Rutin | Luteolin_7_O_Glucoside |
|------------------|--------------|-------|------------------------|
| \( \Delta E_{\text{vdW}} \) | -47.63 ± 6.78 | -35.32 ± 2.91 | -40.88 ± 5.98 |
| \( \Delta E_{\text{ele}} \) | -39.57 ± 6.32 | -40.47 ± 6.57 | -40.47 ± 2.91 |
| \( \Delta E_{\text{PSE}} \) | 85.42 ± 11.35 | 77.30 ± 12.81 | 56.68 ± 7.23 |
| \( \Delta E_{\text{SASA}} \) | -5.98 ± 0.39 | -4.72 ± 0.44 | -4.57 ± 0.50 |
| \( \Delta E_{\text{BE}} \) | -7.76 ± 5.95 | -3.22 ± 3.22 | -15.00 ± 5.58 |

\( \Delta E_{\text{vdW}} \): van der Waal energy, \( \Delta E_{\text{ele}} \): Electrostatic energy, \( \Delta E_{\text{PSE}} \): Polar solvation energy, \( \Delta E_{\text{SASA}} \): Solvent accessible surface area energy, \( \Delta E_{\text{BE}} \): Binding energy.

The MM-PBSA calculations were further used to identify the major energy contributing amino acids of PKM2 (Table 7). Thr50, Pro53, Ser77, His78, Asp113, Thr114, Glu118, Val176, Asp177, Val209, Glu332, and Ala366 of PKM2 were the major energy contributors for the binding of Ver (Figure 6B–D). In the PKM2-Rut complex, Thr328, Gln329, Ile335, Gly363, and Glu364 were the major energy contributors (Figure 6C). Similarly, the binding of PKM2-Lut complex was mostly contributed by Thr50, Pro53, Leu74, His78, Gly79, Tyr83, and Ala366 residues (Figure 6D). It is interesting to note that the polar energy of some of these highest energy contributors was found to be positive, showing that the polar energies of these residues impaired the overall interaction.

Table 7. Total binding energies (kcal mol\(^{-1}\)) of major energy contributors for the interaction of ligands with PKM2 calculated from MM-PBSA.

| Residues     | Luteolin_7_O_Glucoside | Rutin | Verbascoside |
|--------------|------------------------|-------|--------------|
| Residues     | \( E_{\text{total}} \) | \( E_{\text{total}} \) | \( E_{\text{total}} \) |
| Thr50        | -0.71 ± 0.04           | -0.68 ± 0.06 | -0.72 ± 0.02 |
| Pro53        | -1.96 ± 0.04           | -0.80 ± 0.11 | -0.68 ± 0.02 |
| Leu74        | -0.63 ± 0.04           | -1.38 ± 0.07 | -0.59 ± 0.08 |
| His78        | -1.87 ± 0.09           | -0.61 ± 0.05 | -0.54 ± 0.05 |
| Gly79        | -0.52 ± 0.04           | -0.55 ± 0.25 | -0.81 ± 0.17 |
| Tyr83        | -2.20 ± 0.12           | -0.73 ± 0.06 | -0.73 ± 0.06 |
| Ala366       | -0.77 ± 0.05           | -1.11 ± 0.05 | -0.59 ± 0.03 |

\( E_{\text{total}} \): Total energy.

3.5. Principal Component Analysis

Principal component analysis (PCA) is one of the most common standard statistical procedures to study the large-scale motion of proteins which is performed by reducing the dimensionality of data sets without losing the important information, which is characterised by eigenvectors [43]. PCA was done to analyse the differences in flexibility parameters in PKM2 and its complexes as shown in Figure 7A. All complexes and PKM alone occupied a conformational space in the projection of eigenvectors. In PCA analysis, larger conformational space denotes more structural flexibility of the proteins/complexes. This shows that the PKM2-Rut complex exhibited the highest structural flexibility compared with other complexes. The free energy landscapes were made from eigenvectors of PCA analysis to decipher the protein folding patterns. The free energy landscapes of PKM2 alone and complexes are presented in Figure 7B–E. The landscapes showed that all systems reached energy minima during MD simulation. However, there were certain differences in the position of energy minima showing the variations in their conformation. The lowest
energy minima of all systems were used to extract the lowest energy structures from the respective trajectories. The Ramachandran plots for lowest energy structures are shown in Figure 8A–D. The average phi (φ) and psi (ψ) angles for PKM2 alone were found to be $-77.93$ and $36.58$ degrees. Similarly, the average φ & ψ angles for PKM2-Ver, PKM2-Rut, and PKM2-Lut complexes were obtained as $-77.16$ & $35.55$, $-77.35$ & $37.19$, and $-79.58$ & $38.70$, respectively. The negligible differences between these values show that energy minima structures of all systems were approximately equally stable, and PKM2 did not undergo any major structural transformation after the binding with the ligand molecules. A slight variation in these dihedral angles of complexes compared with PKM2 alone denotes a slight dynamical shift in the conformation of PKM2 after the interaction of ligands.

![Figure 7. (A) Principal component analysis (PCA) of PKM2 in the absence and presence of Ver, Rut, and Lut. (B) Free energy landscape plot of PKM2 alone. (C) Free energy landscape plot of PKM2-Lut complex. (D) Free energy landscape plot of PKM2-Rut complex. (E) Free energy landscape plot of PKM2-Ver complex.](image)

![Figure 8. (A) Ramachandran plot of the energy minima structures of PKM2 alone. (B) Ramachandran plot of the energy minima structures of PKM2-Ver complex. (C) Ramachandran plot of the energy minima structures of PKM2-Lut complex. (D) Ramachandran plot of the energy minima structures of PKM2-Rut complex.](image)

4. Conclusions

Medicinal plants have played an important role in the discovery of approximately 50% of anticancer drugs. The phytocompounds of OLE have a protective effect against cancer in humans. This study intends to explore the potential lead molecules from OLE as
PKM2 protein inhibitors against cancers by using in-silico approaches. The top three OLE phytochemicals, Ver, Rut, and Lut, have higher binding affinities with PKM2 proteins in docking. The inhibition constant of these top three phytochemicals against PKM2 were recorded as 46, 64, and 296 nmol/L. The molecular dynamics simulations show that the ligands exhibited dynamical shift for their specific initial positions at the catalytic site of the protein. These data clearly support the strong affinity of these compounds with PKM2 that needs to be further tested under in vitro and in vivo models. The ADME properties of the top three phytochemicals, predicted using the pkCSM web server, indicated relevant pharmaceutical properties. Moreover, the PASS Online software shows the prodigious probability of hit compounds to inhibit the protein and their antineoplastic properties also indicate elevated possibilities of anticancer activity. The MM-PBSA energy calculations support the strong binding of the potential lead molecules with the PKM2 protein. Based on the data, out the three hit compounds, we cannot be sure to label one compound as having the most potential, since one compound ranked better in one parameter, while other compounds were good in other properties. Hence, we propose Ver, Rut, and Lut as potential lead compounds for further study in the drug development process with the PKM2 protein against cancer.

Author Contributions: F.A.Q. and S.Y.A. contributed to the study conception and design. Material preparation, data collection and analysis were performed by F.A.Q., S.Y.A., M.A.I. and M.A.H. The first draft of the manuscript was written by F.A.Q. and all authors commented on previous versions of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This project was supported by the Researchers Supporting Project number (RSP-2021/35), King Saud University, Riyadh, Saudi Arabia.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The raw data of this manuscript is available by corresponding author upon request.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Not applicable.

Abbreviations

| Abbreviation | Full Form |
|--------------|-----------|
| ADME         | Absorption, distribution, metabolism, excretion |
| Lut          | Luteolin_7_O-glucoside |
| OLE          | Olive leaves extract |
| PKM2         | Pyruvate kinase M2 isoform |
| Rut          | Rutin |
| Ver          | Verbascoside |

References

1. Globocan GLOBOCAN 2020: New Global Cancer Data. Available online: https://www.uicc.org/news/globocan-2020-new-global-cancer-data (accessed on 26 August 2022).
2. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef] [PubMed]
3. Liberti, M.V.; Locasale, J.W. The Warburg Effect: How Does It Benefit Cancer Cells? Trends Biochem. Sci. 2016, 41, 211–218. [CrossRef] [PubMed]
4. Zhu, S.; Guo, Y.; Zhang, X.; Liu, H.; Yin, M.; Chen, X.; Peng, C. Pyruvate Kinase M2 (PKM2) in Cancer and Cancer Therapeutics. Cancer Lett. 2021, 503, 240–248. [CrossRef]
5. Dayton, T.L.; Jacks, T.; Vander Heiden, M.G. PKM 2, Cancer Metabolism, and the Road Ahead. EMBO Rep. 2016, 17, 1721–1730. [CrossRef] [PubMed]
6. Keller, K.E.; Tan, I.S.; Lee, Y.-S. SAICAR Stimulates Pyruvate Kinase Isoform M2 and Promotes Cancer Cell Survival in Glucose-Limited Conditions. Science 2012, 338, 1069–1072. [CrossRef] [PubMed]
7. Talhaoui, N.; Tamalli, A.; Gómez-Caravaca, A.M.; Fernández-Gutiérrez, A.; Segura-Carretero, A. Phenolic Compounds in Olive Leaves: Analytical Determination, Biotic and Abiotic Influence, and Health Benefits. Food Res. Int. 2015, 77, 92–108. [CrossRef]

8. Mihailova, A.; Abbado, D.; Pedentchouk, N. Differences in n-Alkane Profiles between Olives and Olive Leaves as Potential Indicators for the Assessment of Olive Leaf Presence in Virgin Olive Oils. Eur. J. Lipid Sci. Technol. 2015, 117, 1480–1485. [CrossRef]

9. Boss, A.; Bishop, K.; Marlow, G.; Barnett, M.; Ferguson, L. Evidence to Support the Anti-Cancer Effect of Olive Leaf Extract and Future Directions. Nutrients 2016, 8, 513. [CrossRef] [PubMed]

10. Wang, B.; Qu, J.; Luo, S.; Feng, S.; Li, T.; Yuan, M.; Huang, Y.; Liao, J.; Yang, R.; Ding, C. Optimization of Ultrasound-Assisted Extraction of Flavonoids from Olive (Olea europaea) Leaves, and Evaluation of Their Antioxidant and Anticancer Activities. Molecules 2018, 23, 2513. [CrossRef]

11. Salama, Z.A.; Aboul-Enein, A.M.; Gaafar, A.A.; Asker, M.S.; Aly, H.F.; Ahmed, H.A. In-Vitro Antioxidant, Antimicrobial and Anticancer Activities of Banana Leaves (Musa Acuminata) and Olive Leaves (Olea europaea L.) as by-Products. Res. J. Pharm. Technol. 2020, 13, 687. [CrossRef]

12. Antoniou, C.; Hull, J. The Anti-Cancer Effect of Olea europaea L. Products: A Review.Curr. Nutr. Rep. 2021, 10, 99–124. [CrossRef]

13. Fu, S.; Arrázê-Roman, D.; Segura-Carretero, A.; Menéndez, J.A.; Menéndez-Gutiérrez, M.P.; Micó, V.; Fernández-Gutiérrez, A. Qualitative Screening of Phenolic Compounds in Olive Leaf Extracts by Hyphenated Liquid Chromatography and Preliminary Evaluation of Cytotoxic Activity against Human Breast Cancer Cells. Anal. Bioanal. Chem. 2010, 397, 643–654. [CrossRef]

14. Quirantes-Pine, R.; Lozano-Sánchez, J.; Herrero, M.; Ibáñez, E.; Segura-Carretero, A.; Fernández-Gutiérrez, A. HPLC-ESI-QTOF-MS as a Powerful Analytical Tool for Characterising Phenolic Compounds in Olive-Leaf Extracts. Phytochem. Anal. 2013, 24, 213–223. [CrossRef]

15. Martín-García, B.; Verardo, V.; León, L.; de la Rosa, R.; Arráez-Román, D.; Segura-Carretero, A.; Gómez-Caravaca, A.M. GC-QTOF-MS as Valuable Tool to Evaluate the Cultivar and Sample Time on Olive Leaves Triterpenic Components. Food Res. Int. 2019, 115, 219–226. [CrossRef]

16. Olmo-Garcia, L.; Kessler, N.; Neuweger, H.; Wendt, K.; Olmo-Peinado, J.; Fernández-Gutiérrez, A.; Baessmann, C.; Carrasco-Pancorbo, A. Unravelling the Distribution of Secondary Metabolites in Olea europaea L.: Exhaustive Characterization of Eight Olive-Tree Derived Matrices by Complementary Platforms (LC-ESI/APCI-MS and GC-APCI-MS). Molecules 2018, 23, 2419. [CrossRef] [PubMed]

17. Alaño, M.E.; Ivanović, M.; Gómez-Caravaca, A.M.; Arráez-Román, D.; Segura-Carretero, A. Choline Chloride Derivative-Based Deep Eutectic Liquids as Novel Green Alternative Solvents for Extraction of Phenolic Compounds from Olive Leaf. Arab. J. Chem. 2020, 13, 1685–1701. [CrossRef]

18. Meirinhos, J.; Silva, B.M.; Valente, P.; Seabra, R.M.; Pereira, J.A.; Dias, A.; Andrade, P.B.; Ferreres, F. Analysis and Quantitation of Flavonoidic Compounds from Portuguese Olive (Olea europaea L.) Leaf Cultivars. Nat. Prod. Res. 2005, 19, 189–195. [CrossRef]

19. Ghomari, O.; Sourni, F.; Massaoudi, Y.; Ghanam, J.; Drissi Kaitouni, L.B.; Merzouki, M.; Benlemlih, M. Phenolic Profile (HPLC-UV) of Olive Leaves According to Extraction Procedure and Assessment of Antibacterial Activity. Biotechnol. Rep. 2019, 23, e00347. [CrossRef] [PubMed]

20. Brahmi, F.; Mechri, B.; Dhibi, M.; Hammami, M. Variations in Phenolic Compounds and Antiradical Scavenging Activity of Olea europaea Leaves and Fruits Extracts Collected in Two Different Seasons. Ind. Crops Prod. 2013, 49, 256–264. [CrossRef]

21. Servili, M.; Sordini, B.; Esposto, S.; Urbani, S.; Veneziani, G.; Di Maio, I.; Selvaggini, R.; Taticchi, A. Biological Activities of Phenolic Compounds of Extra Virgin Olive Oil. Antioxidants 2013, 3, 1–23. [CrossRef] [PubMed]

22. Ortega-García, F.; Peragón, J. Phenol Metabolism in the Leaves of the Olive Tree (Olea europaea L.) Leaf Cultivars. J. Agric. Food Chem. 2010, 58, 12440–12448. [CrossRef]

23. Petersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera?A Visualization System for Exploratory Research and Analysis. J. Comput. Chem. 2004, 25, 1605–1612. [CrossRef]

24. Pires, D.E.V.; Blundell, T.L.; Ascher, D.B. PKCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J. Med. Chem. 2015, 58, 4066–4072. [CrossRef]

25. Wang, Y.; Xing, J.; Xu, Y.; Zhou, N.; Peng, J.; Xiong, Z.; Liu, X.; Luo, C.; Chen, K.; et al. In Silico ADME/T Modelling for Rational Drug Design. Q. Rev. Biophys. 2015, 48, 488–515. [CrossRef]

26. Filimonov, D.A.; Lagunin, A.A.; Glorioso, T.A.; Rudik, A.V.; Druzhilovskii, D.S.; Pogodin, P.V.; Poroikov, V.V. Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web Resource. Chem. Heterocycl. Compd. 2014, 50, 444–457. [CrossRef]

27. Trott, O.; Olson, A.J. AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading. J. Comput. Chem. 2009, 31, 455–461. [CrossRef]

28. Wallace, A.C.; Laskowski, R.A.; Thornton, J.M. LIGPLOT: A Program to Generate Diagrams of Protein-Ligand Interactions The LIGPLOT Program Automatically Generates Schematic 2-D Representations of Protein-Ligand Complexes from Standard Protein Data Bank File Input. Protein Eng. 1995, 8, 127–134. [CrossRef]

29. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. J. Comput. Chem. 2009, 30, 2785–2791. [CrossRef] [PubMed]

30. Warren, L.; DeLano, P.D. PyMOL: An Open-Source Molecular Graphics Tool. Ccp4.Ac.Uk. 2002. Available online: http://legacy.ccp4.ac.uk/newsletters/newsletter40/11_pymol.pdf (accessed on 26 August 2022).
31. Berendsen, H.J.C.; van der Spoel, D.; van Drunen, R. GROMACS: A Message-Passing Parallel Molecular Dynamics Implementation. *Comput. Phys. Commun.* **1995**, *91*, 45–56. [CrossRef]

32. Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, C. Comparison of Multiple Amber Force Fields and Development of Improved Protein Backbone Parameters. *Proteins Struct. Funct. Bioinforma.* **2006**, *65*, 712–725. [CrossRef]

33. Sousa Da Silva, A.W.; Vranken, W.F. ACPYPE—AnteChamber PYthon Parser Interface. *BMC Res. Notes* **2012**, [CrossRef]

34. Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, C. Comparison of Multiple Amber Force Fields and Development of Improved Protein Backbone Parameters. *Proteins Struct. Funct. Bioinforma.* **2006**, *65*, 712–725. [CrossRef]

35. Sousa Da Silva, A.W.; Vranken, W.F. ACPYPE—AnteChamber PYthon Parser Interface. *BMC Res. Notes* **2012**, [CrossRef]

36. Kumari, R.; Kumar, R.; Lynn, A. G_mmpbsa—A GROMACS Tool for High-Throughput MM-PBSA Calculations. *J. Chem. Inf. Model.* **2014**, *54*, 1951–1962. [CrossRef]

37. Liao, S.-Y.; Mo, G.-Q.; Chen, J.-C.; Zheng, K.-C. Exploration of the Binding Mode between (−)-Zampanolide and Tubulin Using Docking and Molecular Dynamics Simulation. *J. Mol. Model.* **2014**, *20*, 2070. [CrossRef]

38. Qais, F.A.; Sarwar, T.; Ahmad, I.; Khan, R.A.; Shahzad, S.A.; Husain, F.M. Glyburide Inhibits Non-Enzymatic Glycation of HSA: An Approach for the Management of AGEs Associated Diabetic Complications. *Int. J. Biol. Macromol.* **2021**, *169*, 143–152. [CrossRef]

39. Fouedjou, R.T.; Chtita, S.; Bakhouch, M.; Belaidi, S.; Ouassaf, M.; Djoumbissie, L.A.; Tapondjou, L.A.; Abul Qais, F. Cameroonian Medicinal Plants as Potential Candidates of SARS-CoV-2 Inhibitors. *J. Biomol. Struct. Dyn.* **2021**, 1–15. [CrossRef]

40. Siddiqui, S.; Ameen, F.; Jahan, I.; Nayeem, S.M.; Tabish, M. A Comprehensive Spectroscopic and Computational Investigation on the Binding of the Anti-Asthmatic Drug Triamcinolone with Serum Albumin. *New J. Chem.* **2019**, *43*, 4137–4151. [CrossRef]

41. Ding, K.; Zhang, H.; Wang, H.; Lv, X.; Pan, L.; Zhang, W.; Zhuang, S. Atomic-Scale Investigation of the Interactions between Tetrabromobisphenol A, Tetrabromobisphenol S and Bovine Trypsin by Spectroscopies and Molecular Dynamics Simulations. *J. Hazard. Mater.* **2015**, *299*, 486–494. [CrossRef]

42. Rath, B.; Abul Qais, F.; Patro, R.; Mohapatra, S.; Sharma, T. Design, Synthesis and Molecular Modeling Studies of Novel Mesalamine Linked Coumarin for Treatment of Inflammatory Bowel Disease. *Bioorg. Med. Chem. Lett.* **2021**, *128029*. [CrossRef] [PubMed]

43. Siddiqui, S.; Ameen, F.; Kausar, T.; Nayeem, S.M.; Ur Rehman, S.; Tabish, M. Biophysical Insight into the Binding Mechanism of Doxofylline to Bovine Serum Albumin: An In Vitro and in Silico Approach. *Spectrochim. Acta Part A Mol. Biomol. Spectrosc.* **2021**, *249*, 119296. [CrossRef] [PubMed]